Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, India.
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research, Jamia Hamdard (Deemed-to-be-University), New Delhi, India.
Arch Pharm (Weinheim). 2020 Aug;353(8):e2000081. doi: 10.1002/ardp.202000081. Epub 2020 May 25.
Postmenopausal women are at high risk of developing breast cancer due to estrogen production in peripheral tissues of the body other than ovaries. Aromatase is present in breast tissue, leading to local estrogen production which can be inhibited by a variety of steroidal and nonsteroidal aromatase inhibitors. There are many aromatase inhibitors available in clinical practice like exemestane, formestane, anastrozole, letrozole, fadrozole, vorozole, and so forth, but the major challenge in anti-breast cancer therapy is the toxicity associated with aromatase inhibitors, especially the steroidal class of drugs. It is, therefore, urgently required to develop novel anticancer drugs having better safety and efficacy for the treatment of breast cancer. This study highlights the aromatase inhibitors reported in the current literature as well as the recent advances in the management of breast cancer.
绝经后妇女由于身体除卵巢以外的外周组织产生雌激素，因此患乳腺癌的风险很高。芳香酶存在于乳腺组织中，导致局部雌激素产生，而各种甾体和非甾体芳香酶抑制剂可以抑制这种产生。临床上有许多芳香酶抑制剂，如依西美坦、福美坦、阿那曲唑、来曲唑、法倔唑、伏罗唑等，但抗乳腺癌治疗的主要挑战是与芳香酶抑制剂相关的毒性，特别是甾体类药物。因此，迫切需要开发具有更好安全性和疗效的新型抗癌药物来治疗乳腺癌。本研究重点介绍了当前文献中报道的芳香酶抑制剂以及乳腺癌治疗的最新进展。
